The Eugene M. and Christine E. Lynn Cancer Institute recently installed the AccuBoost breast cancer radiotherapy system. The system is located at the Harvey & Phyllis Sandler Pavilion, home of the Lynn Cancer Institute.
The Lynn Cancer Institute acquired the technology as a result of an analysis done by Rashmi Benda, M.D., a radiation oncologist on staff at Boca Raton Community Hospital, on the potential impact the AccuBoost technology could offer to patients.
Women with early stage breast cancer increasingly choose breast conservation therapy (BCT). In the BCT option, the cancerous tumor is surgically removed in a procedure known as lumpectomy. Following a lumpectomy, most women undergo whole breast irradiation (WBI), which includes a very important “boost” phase. The boost dose is an important component of the full course of radiation therapy and is delivered to the tissue adjacent to the surgical excision site, a region from which most recurrences originate. The added boost dose to the surgical margin has been shown to provide additional protection against recurrence.
AccuBoost is designed to target and deliver the all-important boost dose accurately and reliably. The AccuBoost system is an image-guided radiation therapy (IGRT) technique that uses non invasive high-dose rate (HDR) brachytherapy to deliver a focused dose to the lumpectomy site. By virtue of directly and precisely targeting the treatment area, patients who have used the AccuBoost system have less reddening of the skin.
The Eugene M. and Christine E. Lynn Cancer Institute recently installed the AccuBoost breast cancer radiotherapy system. The system is located at the Harvey & Phyllis Sandler Pavilion, home of the Lynn Cancer Institute. 
